Europe’s BCMA-targeted therapies market is growing steadily, driven by advancements in immunotherapy and the rising prevalence of multiple myeloma. The European market includes key players and growing interest in BCMA-based treatments, such as CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs). With increasing regulatory support, Europe is expected to see...
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian